Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bimatoprost. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR known ✓ | P43088 | 8/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 1/20 | 1.00 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.80 |
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.63 |
| ▸ | MGLL | Q99685 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.59 |
| ▸ | SLCO2A1 | Q92959 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.59 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.57 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bimatoprost SCHEMBL12087441 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL10015911 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL399000 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL24425 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL10071021 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL11977332 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL13187412 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL20434484 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL22364345 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL12076308 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160113942-A1 | COMPOSITIONS COMPRISING A PROSTAGLANDIN FOR TREATING NEUROPSYCHIATRIC CONDITIONS | INCEPTUM RESEARCH & THERAPEUTICS, INC. (CA) | 2016-04-28 | — | — | US | claimed |
| US-20130309330-A1 | COMPOSITIONS COMPRISING A PROSTAGLANDIN FOR TREATING NEUROPSYCHIATRIC CONDITIONS | INCEPTUM RESEARCH & THERAPEUTICS, INC. (CA) | 2013-11-21 | — | — | US | claimed |
| EP-4100014-B1 | COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION | NICOX SA (FR) | 2024-01-03 | — | — | EP | disclosed |
| EP-4285908-A2 | PHARMACEUTICAL PREPARATION | Alcon Inc. (CH) | 2023-12-06 | — | — | EP | disclosed |
| US-20230241030-A1 | MACROGOL 15 HYDROXYSTEARATE FORMULATIONS | ALLERGAN INC (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230069076-A1 | COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION | NICOX S.A. (FR) | 2023-03-02 | — | — | US | disclosed |
| CN-115038449-A | Compositions for treating glaucoma and ocular hypertension | 尼科斯股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| US-11324757-B2 | Pharmaceutical composition for treatment of increased intraocular pressure | NOVALIQ GMBH (DE) | 2022-05-10 | — | — | US | disclosed |
| EP-3116854-B1 | NEW PROCESS FOR THE PREPARATION OF HIGH PURITY PROSTAGLANDINS | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA ZRT (HU) | 2022-01-26 | — | — | EP | disclosed |
| US-20210275497-A1 | MACROGOL 15 HYDROXYSTEARATE FORMULATIONS | ALLERGAN, INC. | 2021-09-09 | — | — | US | disclosed |
| US-20210052599-A1 | DRUG THERAPY FOR PREVENTING OR TREATING GLAUCOMA | KOWA CO., LTD. (JP) | 2021-02-25 | — | — | US | disclosed |
| US-20120263803-A1 | AQUEOUS OPHTHALMIC COMPOSITION | R-TECH UENO, LTD. (JP) | 2012-10-18 | — | — | US | disclosed |
| US-20120259008-A1 | METHOD FOR TREATING ASTHENOPIA | SUCAMPO AG (CH) | 2012-10-11 | — | — | US | disclosed |
| EP-2497766-A1 | A CRYSTALLINE FORM OF BIMATOPROST, PREPARATION METHOD AND USE THEREOF | Shanghai Techwell Biopharmaceutical Co., Ltd (CN) | 2012-09-12 | — | — | EP | disclosed |
| US-20120087864-A1 | METHOD FOR DIAGNOSING AND/OR EVALUATING RETINAL DISEASE | R-TECH UENO, LTD. (JP) | 2012-04-12 | — | — | US | disclosed |
| US-20110275715-A1 | METHOD FOR TREATING RETINAL DISEASE | R-TECH UENO, LTD. (JP) | 2011-11-10 | — | — | US | disclosed |
| US-20110275711-A1 | METHOD FOR TREATING MACULAR EDEMA | R-TECH UENO, LTD. (JP) | 2011-11-10 | — | — | US | disclosed |
| US-20110130577-A1 | Process for the Preparation of Prostaglandin Analogues and Intermediates Thereof | SCINOPHARM TAIWAN LTD. | 2011-06-02 | — | — | US | disclosed |
| US-7897795-B2 | Process for the preparation of prostaglandin analogues and intermediates thereof | SCINOPHARM TAIWAN LTD. (TW) | 2011-03-01 | — | — | US | disclosed |
| US-20090259058-A1 | Process for the Preparation of Prostaglandin Analogues and Intermediates Thereof | SCINOPHARM TAIWAN LTD. | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090259058-A1 | Process for the Preparation of Prostaglandin Analogues and Intermediates Thereof | PTGIS, PTGES, PTGER1 | PTGFR 13/4885ABCB11 2619/4885AKR1C3 52/4885 |
| US-20120263803-A1 | AQUEOUS OPHTHALMIC COMPOSITION | PTGER1, ELOVL1, EDNRB | PTGFR 135/4885ABCB11 225/4885AKR1C3 651/4885 |
| US-20230069076-A1 | COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION | PTGIS, PDE5A, PDE3A | PTGFR 44/4885ABCB11 4078/4885AKR1C3 1285/4885 |
| US-20110275715-A1 | METHOD FOR TREATING RETINAL DISEASE | ALDH1A2, LIPA, ALDH1A3 | PTGFR 1493/4885ABCB11 2492/4885AKR1C3 622/4885 |
| US-20120259008-A1 | METHOD FOR TREATING ASTHENOPIA | PTGIR, PTGER2, PTGER1 | PTGFR 117/4885ABCB11 1738/4885AKR1C3 249/4885 |
| US-20110275711-A1 | METHOD FOR TREATING MACULAR EDEMA | ALOX5, PTGES, PTGES3 | PTGFR 24/4885ABCB11 4217/4885AKR1C3 193/4885 |
| US-20120087864-A1 | METHOD FOR DIAGNOSING AND/OR EVALUATING RETINAL DISEASE | ALDH1A2, PDE6D, PDE6H | PTGFR 592/4885ABCB11 4589/4885AKR1C3 1209/4885 |
| US-20230241030-A1 | MACROGOL 15 HYDROXYSTEARATE FORMULATIONS | LIPA, CYP27A1, HSD17B13 | PTGFR 4166/4885ABCB11 1556/4885AKR1C3 2135/4885 |
| US-20110130577-A1 | Process for the Preparation of Prostaglandin Analogues and Intermediates Thereof | PTGIS, PTGES, PTGER1 | PTGFR 13/4885ABCB11 2619/4885AKR1C3 52/4885 |
| US-20210275497-A1 | MACROGOL 15 HYDROXYSTEARATE FORMULATIONS | LIPA, CYP27A1, HSD17B13 | PTGFR 4166/4885ABCB11 1556/4885AKR1C3 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.